Literature DB >> 12016144

Unbalanced overexpression of the mutant allele in murine Patched mutants.

Julia Calzada-Wack1, Roland Kappler, Udo Schnitzbauer, Thomas Richter, Michaela Nathrath, Michael Rosemann, Stephan N Wagner, Rüdiger Hein, Heidi Hahn.   

Abstract

Inherited mutations of Patched (PTCH) in the nevoid basal cell carcinoma syndrome (NBCCS) lead to several developmental defects and contribute to tumor formation in a variety of tissues. PTCH mutations have been also identified in sporadic tumors associated with NBCCS including basal cell carcinoma (BCC) and medulloblastoma. Mice heterozygous for Ptch recapitulate the typical developmental symptoms of NBCCS and develop rhabdomyosarcoma (RMS) and medulloblastoma. PTCH is assumed to act as a tumor suppressor gene although inactivation of both alleles has been demonstrated only in a fraction of tumors. We have investigated the status of Ptch in RMS of heterozygous Ptch neo67/+ mice. Although the wild-type Ptch allele was retained in tumor tissue, the high levels of Ptch mRNA in these tumors result from overexpression of the mutant Ptch transcript. Our results suggest that the wild-type Ptch allele might be selectively silenced in RMS tissue or, alternatively, that haploinsufficiency of Ptch is sufficient to promote RMS formation in mice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12016144     DOI: 10.1093/carcin/23.5.727

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  13 in total

Review 1.  Medulloblastoma-biology and microenvironment: a review.

Authors:  Tiara Byrd; Robert G Grossman; Nabil Ahmed
Journal:  Pediatr Hematol Oncol       Date:  2012-06-28       Impact factor: 1.969

2.  Zebrafish models of rhabdomyosarcoma.

Authors:  Eleanor Y Chen; David M Langenau
Journal:  Methods Cell Biol       Date:  2011       Impact factor: 1.441

Review 3.  Developmental origins of fusion-negative rhabdomyosarcomas.

Authors:  Ken Kikuchi; Brian P Rubin; Charles Keller
Journal:  Curr Top Dev Biol       Date:  2011       Impact factor: 4.897

4.  Medulloblastoma.

Authors:  Catherine A. Mazzola; Ian F. Pollack
Journal:  Curr Treat Options Neurol       Date:  2003-05       Impact factor: 3.598

5.  Loss of Blm enhances basal cell carcinoma and rhabdomyosarcoma tumorigenesis in Ptch1+/- mice.

Authors:  Parastoo Davari; Jennifer L Hebert; Donna G Albertson; Bing Huey; Ritu Roy; Maria L Mancianti; Andrew E Horvai; Lisa D McDaniel; Roger A Schultz; Ervin H Epstein
Journal:  Carcinogenesis       Date:  2009-12-08       Impact factor: 4.944

6.  Congenital embryonal rhabdomyosarcoma caused by heterozygous concomitant PTCH1 and PTCH2 germline mutations.

Authors:  Julia Taeubner; Triantafyllia Brozou; Nan Qin; Jasmin Bartl; Sebastian Ginzel; Joerg Schaper; Joerg Felsberg; Simone Fulda; Christian Vokuhl; Arndt Borkhardt; Michaela Kuhlen
Journal:  Eur J Hum Genet       Date:  2017-12-11       Impact factor: 4.246

7.  c-Myc enhances sonic hedgehog-induced medulloblastoma formation from nestin-expressing neural progenitors in mice.

Authors:  Ganesh Rao; Carolyn A Pedone; Cheryl M Coffin; Eric C Holland; Daniel W Fults
Journal:  Neoplasia       Date:  2003 May-Jun       Impact factor: 5.715

8.  Calcitriol inhibits hedgehog signaling and induces vitamin d receptor signaling and differentiation in the patched mouse model of embryonal rhabdomyosarcoma.

Authors:  Anja Uhmann; Hannah Niemann; Bérénice Lammering; Cornelia Henkel; Ina Heß; Albert Rosenberger; Christian Dullin; Anke Schraepler; Walter Schulz-Schaeffer; Heidi Hahn
Journal:  Sarcoma       Date:  2012-02-21

9.  Overexpression of mutant Ptch in rhabdomyosarcomas is associated with promoter hypomethylation and increased Gli1 and H3K4me3 occupancy.

Authors:  Frauke Nitzki; Ezequiel J Tolosa; Nicole Cuvelier; Anke Frommhold; Gabriela Salinas-Riester; Steven A Johnsen; Martin E Fernandez-Zapico; Heidi Hahn
Journal:  Oncotarget       Date:  2015-04-20

10.  Ligand-dependent Hedgehog pathway activation in Rhabdomyosarcoma: the oncogenic role of the ligands.

Authors:  A Almazán-Moga; P Zarzosa; C Molist; P Velasco; J Pyczek; K Simon-Keller; I Giralt; I Vidal; N Navarro; M F Segura; A Soriano; S Navarro; O M Tirado; J C Ferreres; A Santamaria; R Rota; H Hahn; J Sánchez de Toledo; J Roma; S Gallego
Journal:  Br J Cancer       Date:  2017-09-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.